Business Segment Information (Tables)

12 Months Ended

Apr. 30, 2013

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following tables summarize, for the periods indicated, operating results by business segment (in thousands):

Year Ended April 30, 2013	Personalized Oncology Solutions (POS)		Translational Oncology Solutions (TOS)		Unallocated Corporate Overhead		Consolidated
Net revenue	$	2,390	$	5,933	$	-	$	8,323
Direct cost of services		(2,604)		(2,637)		-		(5,241)
Sales and marketing costs		(1,496)		(938)		-		(2,434)
Other operating expenses		(134)		(1,753)		(2,606)		(4,493)
Stock compensation expense (1)		-		-		(2,376)		(2,376)
Segment profit (loss)	$	(1,844)	$	605	$	(4,982)	$	(6,221)

Year Ended April 30, 2012	Personalized Oncology Solutions (POS)		Translational Oncology Solutions (TOS)		Unallocated Corporate Overhead		Consolidated
Net revenue	$	2,332	$	4,817	$	-	$	7,149
Direct cost of services		(2,331)		(2,533)		-		(4,864)
Sales and marketing costs		(1,752)		(936)		-		(2,688)
Other operating expenses		-		(2,898)		(2,441)		(5,339)
Stock compensation expense (1)		-		-		(3,323)		(3,323)
Segment loss	$	(1,751)	$	(1,550)	$	(5,764)	$	(9,065)

(1) Stock compensation expense is shown separately and is excluded from direct costs of services, sales and marketing costs, and other operating expenses, as it is managed on a consolidated basis and is not used by management to evaluate the performance of its segments.